| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Function, Left | 52 | 2025 | 268 | 6.160 |
Why?
|
| Ventricular Dysfunction, Left | 36 | 2025 | 165 | 6.040 |
Why?
|
| Echocardiography | 75 | 2025 | 503 | 6.010 |
Why?
|
| Stroke Volume | 45 | 2025 | 329 | 3.900 |
Why?
|
| Hypertension | 42 | 2024 | 590 | 3.770 |
Why?
|
| Echocardiography, Doppler | 41 | 2024 | 133 | 3.670 |
Why?
|
| Hypertrophy, Left Ventricular | 37 | 2023 | 124 | 3.530 |
Why?
|
| Heart Ventricles | 35 | 2025 | 263 | 3.530 |
Why?
|
| Diastole | 28 | 2024 | 91 | 3.150 |
Why?
|
| Aortic Valve Stenosis | 20 | 2021 | 188 | 3.020 |
Why?
|
| Heart Failure | 41 | 2024 | 921 | 2.950 |
Why?
|
| Ventricular Remodeling | 13 | 2021 | 88 | 2.630 |
Why?
|
| Takotsubo Cardiomyopathy | 8 | 2023 | 66 | 2.550 |
Why?
|
| Heart Valve Diseases | 9 | 2024 | 95 | 1.890 |
Why?
|
| Systole | 26 | 2021 | 108 | 1.860 |
Why?
|
| Cardiomyopathies | 7 | 2024 | 129 | 1.580 |
Why?
|
| Myocardial Contraction | 19 | 2012 | 89 | 1.520 |
Why?
|
| Aortic Valve | 10 | 2021 | 190 | 1.450 |
Why?
|
| Ventricular Pressure | 9 | 2024 | 31 | 1.410 |
Why?
|
| Humans | 187 | 2025 | 63527 | 1.360 |
Why?
|
| Echocardiography, Three-Dimensional | 5 | 2024 | 44 | 1.360 |
Why?
|
| Aortic Valve Insufficiency | 10 | 2020 | 43 | 1.230 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2023 | 108 | 1.200 |
Why?
|
| Heart Atria | 11 | 2023 | 136 | 1.200 |
Why?
|
| Mitral Valve Insufficiency | 12 | 2024 | 92 | 1.130 |
Why?
|
| Antihypertensive Agents | 13 | 2021 | 172 | 1.080 |
Why?
|
| Aged | 91 | 2024 | 14451 | 1.040 |
Why?
|
| Female | 110 | 2025 | 32939 | 0.990 |
Why?
|
| Heart Diseases | 8 | 2019 | 219 | 0.930 |
Why?
|
| Elasticity Imaging Techniques | 2 | 2016 | 26 | 0.870 |
Why?
|
| Atrial Function, Left | 6 | 2024 | 32 | 0.870 |
Why?
|
| Heart | 7 | 2019 | 287 | 0.850 |
Why?
|
| Cardiac Catheterization | 13 | 2024 | 287 | 0.830 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 5468 | 0.820 |
Why?
|
| Male | 103 | 2024 | 29931 | 0.820 |
Why?
|
| Diagnostic Imaging | 5 | 2013 | 265 | 0.790 |
Why?
|
| Predictive Value of Tests | 13 | 2024 | 1090 | 0.760 |
Why?
|
| Obesity | 7 | 2019 | 1234 | 0.740 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 844 | 0.740 |
Why?
|
| Atrial Fibrillation | 8 | 2020 | 833 | 0.730 |
Why?
|
| Hypertension, Pulmonary | 3 | 2021 | 95 | 0.730 |
Why?
|
| Middle Aged | 76 | 2024 | 17656 | 0.730 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2016 | 53 | 0.670 |
Why?
|
| Myocardium | 8 | 2017 | 286 | 0.670 |
Why?
|
| Pheochromocytoma | 1 | 2020 | 31 | 0.660 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2020 | 7 | 0.660 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 48 | 0.660 |
Why?
|
| Myocarditis | 1 | 2021 | 67 | 0.650 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 9 | 0.630 |
Why?
|
| Heart Valves | 3 | 2018 | 26 | 0.610 |
Why?
|
| Mitral Valve | 11 | 2024 | 125 | 0.600 |
Why?
|
| Atrial Pressure | 1 | 2019 | 6 | 0.600 |
Why?
|
| Retrospective Studies | 21 | 2024 | 6619 | 0.590 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 110 | 0.590 |
Why?
|
| Renin-Angiotensin System | 3 | 2011 | 22 | 0.560 |
Why?
|
| Dilatation | 2 | 2016 | 31 | 0.530 |
Why?
|
| Blood Pressure | 15 | 2021 | 514 | 0.530 |
Why?
|
| Calcium | 1 | 2020 | 576 | 0.520 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2025 | 769 | 0.510 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 2463 | 0.510 |
Why?
|
| Reproducibility of Results | 10 | 2024 | 1664 | 0.510 |
Why?
|
| Practice Guidelines as Topic | 6 | 2019 | 721 | 0.500 |
Why?
|
| Hyperaldosteronism | 1 | 2016 | 9 | 0.500 |
Why?
|
| Losartan | 7 | 2014 | 19 | 0.500 |
Why?
|
| Mitoxantrone | 1 | 2016 | 16 | 0.500 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 253 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2025 | 2184 | 0.470 |
Why?
|
| Algorithms | 5 | 2017 | 1004 | 0.470 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2023 | 143 | 0.450 |
Why?
|
| Angiotensin Receptor Antagonists | 3 | 2024 | 65 | 0.440 |
Why?
|
| Treatment Outcome | 16 | 2021 | 5627 | 0.430 |
Why?
|
| Prevalence | 15 | 2021 | 1383 | 0.430 |
Why?
|
| Extracellular Matrix | 1 | 2015 | 139 | 0.420 |
Why?
|
| Myocardial Infarction | 12 | 2021 | 913 | 0.420 |
Why?
|
| Risk Factors | 24 | 2021 | 5282 | 0.410 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 188 | 0.410 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2012 | 180 | 0.410 |
Why?
|
| Aging | 4 | 2011 | 744 | 0.390 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2024 | 35 | 0.380 |
Why?
|
| Heart Failure, Diastolic | 2 | 2010 | 9 | 0.380 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2013 | 107 | 0.370 |
Why?
|
| Heart Valve Prosthesis | 7 | 2021 | 113 | 0.370 |
Why?
|
| Heart Valve Prosthesis Implantation | 3 | 2018 | 175 | 0.350 |
Why?
|
| Gated Blood-Pool Imaging | 2 | 2009 | 11 | 0.350 |
Why?
|
| Aorta | 2 | 2021 | 110 | 0.340 |
Why?
|
| Electrocardiography | 15 | 2024 | 551 | 0.340 |
Why?
|
| Cardiology | 4 | 2022 | 168 | 0.330 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2010 | 33 | 0.320 |
Why?
|
| Incidence | 11 | 2021 | 1372 | 0.310 |
Why?
|
| Survival Rate | 8 | 2018 | 853 | 0.300 |
Why?
|
| Electric Countershock | 2 | 2012 | 102 | 0.300 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2018 | 659 | 0.300 |
Why?
|
| Diagnosis, Differential | 9 | 2013 | 980 | 0.290 |
Why?
|
| Adult | 31 | 2025 | 16895 | 0.290 |
Why?
|
| Prognosis | 18 | 2023 | 1743 | 0.290 |
Why?
|
| Organ Size | 6 | 2014 | 170 | 0.280 |
Why?
|
| Age Factors | 10 | 2021 | 1561 | 0.280 |
Why?
|
| Cardiac Volume | 1 | 2007 | 7 | 0.280 |
Why?
|
| Phenotype | 3 | 2025 | 1208 | 0.280 |
Why?
|
| Conscious Sedation | 2 | 2004 | 39 | 0.270 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2025 | 361 | 0.270 |
Why?
|
| Pulmonary Artery | 3 | 2021 | 96 | 0.260 |
Why?
|
| Time Factors | 13 | 2021 | 3708 | 0.260 |
Why?
|
| Sensitivity and Specificity | 8 | 2016 | 1151 | 0.250 |
Why?
|
| Ventricular Dysfunction, Right | 3 | 2017 | 49 | 0.250 |
Why?
|
| Catheter Ablation | 3 | 2024 | 153 | 0.240 |
Why?
|
| Calcinosis | 3 | 2024 | 86 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 198 | 0.240 |
Why?
|
| Disease Progression | 9 | 2013 | 1170 | 0.240 |
Why?
|
| Geriatric Assessment | 2 | 2004 | 163 | 0.240 |
Why?
|
| Cardiomegaly | 4 | 2016 | 37 | 0.230 |
Why?
|
| United States | 15 | 2025 | 7836 | 0.230 |
Why?
|
| Stress, Physiological | 2 | 2009 | 193 | 0.230 |
Why?
|
| Societies, Medical | 5 | 2018 | 378 | 0.220 |
Why?
|
| Dexfenfluramine | 2 | 2002 | 5 | 0.220 |
Why?
|
| Blood Flow Velocity | 5 | 2009 | 71 | 0.220 |
Why?
|
| Ventricular Premature Complexes | 1 | 2024 | 20 | 0.220 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2004 | 111 | 0.210 |
Why?
|
| Endocardium | 4 | 2010 | 13 | 0.210 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.200 |
Why?
|
| Heart Function Tests | 4 | 2005 | 16 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 16 | 0.200 |
Why?
|
| Prospective Studies | 14 | 2016 | 3293 | 0.200 |
Why?
|
| Stress, Psychological | 2 | 2009 | 474 | 0.190 |
Why?
|
| Severity of Illness Index | 8 | 2020 | 1552 | 0.190 |
Why?
|
| Mitral Valve Annuloplasty | 2 | 2020 | 19 | 0.190 |
Why?
|
| Tachycardia, Ventricular | 1 | 2024 | 130 | 0.190 |
Why?
|
| Serotonin Receptor Agonists | 1 | 2002 | 13 | 0.180 |
Why?
|
| Aortic Aneurysm | 2 | 2020 | 82 | 0.180 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2021 | 9 | 0.180 |
Why?
|
| Mitral Valve Prolapse | 1 | 2021 | 11 | 0.180 |
Why?
|
| Heart Rate | 7 | 2010 | 321 | 0.180 |
Why?
|
| Vasodilator Agents | 4 | 2004 | 68 | 0.180 |
Why?
|
| Appetite Depressants | 2 | 1998 | 6 | 0.180 |
Why?
|
| Case-Control Studies | 8 | 2016 | 1120 | 0.180 |
Why?
|
| Obstetric Labor Complications | 1 | 2021 | 23 | 0.180 |
Why?
|
| Sex Factors | 6 | 2021 | 973 | 0.170 |
Why?
|
| Nephritis, Hereditary | 1 | 2020 | 2 | 0.170 |
Why?
|
| Endocarditis | 1 | 2021 | 29 | 0.170 |
Why?
|
| Adrenergic Agents | 1 | 2020 | 15 | 0.170 |
Why?
|
| Advisory Committees | 3 | 2018 | 112 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2021 | 728 | 0.170 |
Why?
|
| Massachusetts | 7 | 2016 | 2072 | 0.170 |
Why?
|
| Atrial Remodeling | 1 | 2020 | 17 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2013 | 410 | 0.160 |
Why?
|
| Contrast Media | 4 | 2010 | 422 | 0.160 |
Why?
|
| Comorbidity | 5 | 2017 | 1114 | 0.160 |
Why?
|
| Hospitalization | 5 | 2021 | 1359 | 0.160 |
Why?
|
| Heart Failure, Systolic | 2 | 2010 | 16 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2021 | 149 | 0.150 |
Why?
|
| Ventricular Dysfunction | 3 | 2006 | 13 | 0.150 |
Why?
|
| Coronary Angiography | 4 | 2013 | 205 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 364 | 0.150 |
Why?
|
| Postoperative Complications | 3 | 2021 | 1278 | 0.140 |
Why?
|
| Registries | 3 | 2021 | 872 | 0.140 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2024 | 102 | 0.140 |
Why?
|
| Hemodynamics | 11 | 2015 | 248 | 0.140 |
Why?
|
| Pacemaker, Artificial | 3 | 2013 | 49 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2012 | 457 | 0.140 |
Why?
|
| Thoracic Surgery | 1 | 2018 | 76 | 0.130 |
Why?
|
| Coronary Vessels | 2 | 2013 | 120 | 0.130 |
Why?
|
| Tetrazoles | 2 | 2007 | 22 | 0.130 |
Why?
|
| Valine | 2 | 2007 | 32 | 0.130 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2007 | 24 | 0.130 |
Why?
|
| Gravidity | 1 | 2016 | 12 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 699 | 0.130 |
Why?
|
| Reproductive History | 1 | 2016 | 17 | 0.130 |
Why?
|
| Menstruation Disturbances | 1 | 2016 | 18 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 226 | 0.130 |
Why?
|
| Heart Defects, Congenital | 2 | 2016 | 103 | 0.130 |
Why?
|
| Analysis of Variance | 5 | 2014 | 605 | 0.130 |
Why?
|
| Aldosterone | 1 | 2016 | 18 | 0.130 |
Why?
|
| Personality | 1 | 2016 | 29 | 0.120 |
Why?
|
| Mathematics | 1 | 2016 | 34 | 0.120 |
Why?
|
| Linear Models | 3 | 2016 | 408 | 0.120 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2016 | 81 | 0.120 |
Why?
|
| Reference Values | 4 | 2009 | 332 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 58 | 0.120 |
Why?
|
| Ventricular Function | 3 | 2010 | 22 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 173 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 1997 | 192 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 2021 | 1535 | 0.120 |
Why?
|
| Stroke | 5 | 2021 | 1184 | 0.110 |
Why?
|
| Coronary Circulation | 2 | 1992 | 52 | 0.110 |
Why?
|
| Coronary Artery Bypass | 2 | 2004 | 297 | 0.110 |
Why?
|
| Observer Variation | 3 | 2019 | 215 | 0.110 |
Why?
|
| Chi-Square Distribution | 5 | 2017 | 411 | 0.110 |
Why?
|
| Europe | 4 | 2015 | 197 | 0.110 |
Why?
|
| Sleep Stages | 1 | 1994 | 16 | 0.110 |
Why?
|
| Mediastinal Diseases | 1 | 1994 | 15 | 0.110 |
Why?
|
| Coronary Disease | 4 | 2003 | 246 | 0.110 |
Why?
|
| Confusion | 1 | 1994 | 17 | 0.110 |
Why?
|
| Exercise Test | 5 | 2004 | 252 | 0.110 |
Why?
|
| HIV Infections | 1 | 2021 | 972 | 0.110 |
Why?
|
| Opioid-Related Disorders | 1 | 2021 | 509 | 0.100 |
Why?
|
| Sex Characteristics | 2 | 1994 | 201 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 692 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 4 | 2021 | 154 | 0.100 |
Why?
|
| Movement Disorders | 1 | 2013 | 24 | 0.100 |
Why?
|
| Anxiety | 1 | 2016 | 429 | 0.100 |
Why?
|
| Hepatic Veins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2013 | 6 | 0.100 |
Why?
|
| Patient Selection | 2 | 2007 | 487 | 0.100 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 931 | 0.100 |
Why?
|
| Elastic Modulus | 1 | 2012 | 38 | 0.100 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2012 | 20 | 0.090 |
Why?
|
| Syndrome | 4 | 2006 | 180 | 0.090 |
Why?
|
| Reference Standards | 3 | 2018 | 73 | 0.090 |
Why?
|
| Coronary Artery Disease | 3 | 2013 | 314 | 0.090 |
Why?
|
| Procollagen | 1 | 2011 | 10 | 0.090 |
Why?
|
| Aortography | 1 | 1992 | 57 | 0.090 |
Why?
|
| Scotland | 1 | 2011 | 9 | 0.090 |
Why?
|
| Collagen Type I | 1 | 2011 | 41 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 2335 | 0.090 |
Why?
|
| Morbidity | 3 | 2017 | 112 | 0.090 |
Why?
|
| Torsades de Pointes | 1 | 2010 | 6 | 0.090 |
Why?
|
| Chronic Disease | 5 | 2005 | 751 | 0.090 |
Why?
|
| Collagen | 1 | 2011 | 123 | 0.090 |
Why?
|
| Serotonin Syndrome | 1 | 2011 | 10 | 0.090 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 662 | 0.080 |
Why?
|
| Logistic Models | 4 | 2021 | 1267 | 0.080 |
Why?
|
| Peripheral Arterial Disease | 1 | 2013 | 157 | 0.080 |
Why?
|
| Long QT Syndrome | 1 | 2010 | 32 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2024 | 147 | 0.080 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 1259 | 0.080 |
Why?
|
| Cardiotonic Agents | 2 | 2009 | 54 | 0.080 |
Why?
|
| Sodium Chloride | 1 | 2010 | 63 | 0.080 |
Why?
|
| Biomarkers | 5 | 2020 | 1405 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2013 | 1641 | 0.080 |
Why?
|
| Angiocardiography | 1 | 2009 | 6 | 0.080 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1989 | 60 | 0.080 |
Why?
|
| Statistics, Nonparametric | 3 | 2006 | 215 | 0.080 |
Why?
|
| Pulmonary Wedge Pressure | 2 | 2008 | 27 | 0.080 |
Why?
|
| Body Surface Area | 1 | 2009 | 11 | 0.080 |
Why?
|
| Body Size | 1 | 2009 | 23 | 0.080 |
Why?
|
| Depression | 1 | 2016 | 908 | 0.080 |
Why?
|
| Patient Education as Topic | 1 | 2013 | 476 | 0.080 |
Why?
|
| Fluorocarbons | 2 | 2000 | 38 | 0.080 |
Why?
|
| Kidney | 1 | 2011 | 448 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2010 | 127 | 0.070 |
Why?
|
| Injections, Intravenous | 3 | 2004 | 156 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2010 | 2026 | 0.070 |
Why?
|
| Fenfluramine | 2 | 1998 | 5 | 0.070 |
Why?
|
| Angina Pectoris | 3 | 2021 | 38 | 0.070 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 1105 | 0.070 |
Why?
|
| Regression Analysis | 5 | 2006 | 498 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 207 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 574 | 0.070 |
Why?
|
| Biomechanical Phenomena | 2 | 2024 | 271 | 0.070 |
Why?
|
| Inpatients | 1 | 2010 | 303 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2013 | 738 | 0.060 |
Why?
|
| Animals | 7 | 2015 | 20715 | 0.060 |
Why?
|
| Catecholamines | 1 | 2006 | 31 | 0.060 |
Why?
|
| Dipyridamole | 2 | 1998 | 17 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 2571 | 0.060 |
Why?
|
| Myocardial Ischemia | 3 | 2003 | 117 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2020 | 584 | 0.060 |
Why?
|
| Ultrasonography | 4 | 2009 | 483 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2021 | 759 | 0.060 |
Why?
|
| Diabetes Mellitus | 3 | 2021 | 541 | 0.060 |
Why?
|
| Midazolam | 1 | 2004 | 12 | 0.060 |
Why?
|
| Recurrence | 3 | 2016 | 640 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2004 | 37 | 0.060 |
Why?
|
| American Heart Association | 1 | 2025 | 126 | 0.060 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 26 | 0.060 |
Why?
|
| Pressure | 1 | 2004 | 78 | 0.050 |
Why?
|
| Peripartum Period | 1 | 2024 | 21 | 0.050 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2004 | 6 | 0.050 |
Why?
|
| Echocardiography, Doppler, Color | 2 | 2004 | 27 | 0.050 |
Why?
|
| Models, Biological | 1 | 2009 | 1182 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2006 | 215 | 0.050 |
Why?
|
| Fentanyl | 1 | 2004 | 76 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2003 | 4 | 0.050 |
Why?
|
| Cardiovascular Agents | 1 | 2004 | 104 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 2584 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 575 | 0.050 |
Why?
|
| Patient Discharge | 2 | 2016 | 503 | 0.050 |
Why?
|
| Viridans Streptococci | 1 | 2002 | 5 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 3 | 1999 | 105 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 103 | 0.050 |
Why?
|
| Atenolol | 2 | 2014 | 9 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2002 | 2 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2002 | 6 | 0.050 |
Why?
|
| Streptococcal Infections | 1 | 2002 | 80 | 0.050 |
Why?
|
| Angiotensin II | 1 | 2002 | 25 | 0.050 |
Why?
|
| Abscess | 1 | 2002 | 80 | 0.050 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 2 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2006 | 775 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 54 | 0.040 |
Why?
|
| Heart Injuries | 2 | 1992 | 19 | 0.040 |
Why?
|
| HIV | 1 | 2021 | 70 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 107 | 0.040 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 21 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2022 | 202 | 0.040 |
Why?
|
| Tubulin | 1 | 2001 | 73 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2020 | 130 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2012 | 620 | 0.040 |
Why?
|
| Arteriosclerosis | 1 | 2000 | 32 | 0.040 |
Why?
|
| Rats | 4 | 2012 | 1991 | 0.040 |
Why?
|
| Curriculum | 2 | 2022 | 599 | 0.040 |
Why?
|
| Syncope | 2 | 1998 | 42 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2021 | 173 | 0.040 |
Why?
|
| Italy | 2 | 2015 | 67 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1999 | 38 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1998 | 20 | 0.040 |
Why?
|
| Chlamydophila pneumoniae | 1 | 1998 | 21 | 0.040 |
Why?
|
| Cause of Death | 2 | 2014 | 221 | 0.040 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 19 | 0.040 |
Why?
|
| Adenosine | 1 | 1998 | 78 | 0.040 |
Why?
|
| Phentermine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Dopamine Agents | 1 | 1998 | 11 | 0.040 |
Why?
|
| Serotonin Agents | 1 | 1998 | 10 | 0.040 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 75 | 0.030 |
Why?
|
| Atrioventricular Node | 1 | 1997 | 9 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1997 | 28 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 1998 | 36 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2021 | 426 | 0.030 |
Why?
|
| Valsartan | 2 | 2007 | 12 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2013 | 79 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 2 | 2000 | 96 | 0.030 |
Why?
|
| Postoperative Period | 2 | 1998 | 137 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 2016 | 23 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 719 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 467 | 0.030 |
Why?
|
| Connecticut | 1 | 2016 | 87 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2016 | 103 | 0.030 |
Why?
|
| Infertility, Female | 1 | 2016 | 46 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2016 | 69 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 418 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 281 | 0.030 |
Why?
|
| New England | 1 | 2016 | 269 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1996 | 42 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 847 | 0.030 |
Why?
|
| Postmenopause | 1 | 2016 | 237 | 0.030 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 1994 | 3 | 0.030 |
Why?
|
| Sinus of Valsalva | 1 | 1994 | 7 | 0.030 |
Why?
|
| Industry | 1 | 2014 | 61 | 0.030 |
Why?
|
| Specialization | 1 | 1995 | 80 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2016 | 151 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 1995 | 186 | 0.030 |
Why?
|
| Death | 1 | 2014 | 31 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 1994 | 117 | 0.030 |
Why?
|
| Motion Pictures | 2 | 1990 | 11 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2013 | 72 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 75 | 0.020 |
Why?
|
| Education, Medical | 1 | 1995 | 185 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2016 | 2702 | 0.020 |
Why?
|
| Hematocrit | 1 | 1992 | 34 | 0.020 |
Why?
|
| Video Recording | 2 | 2005 | 136 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 65 | 0.020 |
Why?
|
| Cineangiography | 1 | 1992 | 2 | 0.020 |
Why?
|
| Acute Disease | 2 | 2010 | 669 | 0.020 |
Why?
|
| Medicare | 2 | 2007 | 612 | 0.020 |
Why?
|
| Arteries | 1 | 2012 | 80 | 0.020 |
Why?
|
| Organometallic Compounds | 1 | 1992 | 66 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2011 | 37 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 1992 | 98 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 4714 | 0.020 |
Why?
|
| Thrombosis | 1 | 1992 | 198 | 0.020 |
Why?
|
| Cardiovascular System | 1 | 2010 | 40 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 868 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 378 | 0.020 |
Why?
|
| Vascular Patency | 1 | 1989 | 133 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2009 | 110 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2011 | 286 | 0.020 |
Why?
|
| Fibrosis | 1 | 2009 | 160 | 0.020 |
Why?
|
| Creatine Kinase | 2 | 2003 | 41 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 1988 | 12 | 0.020 |
Why?
|
| Single-Blind Method | 2 | 1998 | 144 | 0.020 |
Why?
|
| Isoenzymes | 2 | 2003 | 139 | 0.020 |
Why?
|
| Exercise | 1 | 2015 | 946 | 0.020 |
Why?
|
| Mass Screening | 2 | 2003 | 692 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1992 | 863 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 102 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1987 | 294 | 0.020 |
Why?
|
| Health Resources | 1 | 2007 | 95 | 0.020 |
Why?
|
| Physical Exertion | 2 | 1998 | 80 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 36 | 0.010 |
Why?
|
| Health Planning Guidelines | 1 | 2003 | 32 | 0.010 |
Why?
|
| Child | 2 | 2003 | 4541 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2007 | 1015 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 33 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2003 | 25 | 0.010 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2003 | 9 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2003 | 23 | 0.010 |
Why?
|
| Troponin I | 1 | 2003 | 35 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2003 | 85 | 0.010 |
Why?
|
| Homosexuality | 1 | 1982 | 6 | 0.010 |
Why?
|
| Immunoglobulins | 2 | 1998 | 76 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1982 | 19 | 0.010 |
Why?
|
| Necrosis | 1 | 2003 | 145 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 151 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2003 | 182 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1982 | 115 | 0.010 |
Why?
|
| Radionuclide Imaging | 2 | 1992 | 125 | 0.010 |
Why?
|
| Manometry | 1 | 2001 | 25 | 0.010 |
Why?
|
| Evidence-Based Medicine | 1 | 2003 | 460 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2001 | 201 | 0.010 |
Why?
|
| Densitometry | 1 | 2000 | 13 | 0.010 |
Why?
|
| Critical Illness | 1 | 2003 | 318 | 0.010 |
Why?
|
| Safety | 1 | 2000 | 145 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2003 | 1363 | 0.010 |
Why?
|
| Survival | 1 | 1998 | 11 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 12 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 897 | 0.010 |
Why?
|
| Perfusion | 1 | 1998 | 72 | 0.010 |
Why?
|
| Coronary Care Units | 1 | 1998 | 4 | 0.010 |
Why?
|
| Infant | 1 | 2003 | 1654 | 0.010 |
Why?
|
| Health Status | 1 | 2001 | 443 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2003 | 1999 | 0.010 |
Why?
|
| Life Expectancy | 1 | 1998 | 33 | 0.010 |
Why?
|
| Methoxamine | 1 | 1997 | 1 | 0.010 |
Why?
|
| Sick Sinus Syndrome | 1 | 1997 | 5 | 0.010 |
Why?
|
| Atrial Function | 1 | 1997 | 5 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1997 | 37 | 0.010 |
Why?
|
| Heart Block | 1 | 1997 | 22 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 1998 | 181 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 1997 | 36 | 0.010 |
Why?
|
| Body Weight | 1 | 1998 | 379 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1997 | 70 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 233 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 11 | 0.010 |
Why?
|
| Mechanoreceptors | 1 | 1996 | 13 | 0.010 |
Why?
|
| Rome | 1 | 1995 | 2 | 0.010 |
Why?
|
| Fosinopril | 1 | 1995 | 2 | 0.010 |
Why?
|
| Emulsions | 1 | 1998 | 474 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1995 | 186 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2196 | 0.010 |
Why?
|
| Lung | 1 | 1998 | 957 | 0.010 |
Why?
|
| Educational Measurement | 1 | 1995 | 219 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 6259 | 0.010 |
Why?
|
| Indium Radioisotopes | 1 | 1992 | 41 | 0.010 |
Why?
|
| Thoracic Injuries | 1 | 1992 | 45 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1991 | 9 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1992 | 312 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1992 | 113 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 1995 | 864 | 0.010 |
Why?
|
| Wounds, Stab | 1 | 1989 | 14 | 0.000 |
Why?
|
| Heart Septum | 1 | 1989 | 57 | 0.000 |
Why?
|
| Administration, Sublingual | 1 | 1988 | 4 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1988 | 173 | 0.000 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 1987 | 20 | 0.000 |
Why?
|
| Sulfamethizole | 1 | 1982 | 2 | 0.000 |
Why?
|
| Candidiasis, Oral | 1 | 1982 | 6 | 0.000 |
Why?
|
| Trimethoprim | 1 | 1982 | 7 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1982 | 165 | 0.000 |
Why?
|
| California | 1 | 1982 | 174 | 0.000 |
Why?
|
| Cytomegalovirus Infections | 1 | 1982 | 66 | 0.000 |
Why?
|
| Sexually Transmitted Diseases | 1 | 1982 | 96 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1982 | 1009 | 0.000 |
Why?
|